News & Updates

The prespecified final analysis of the phase III CHOICE-01 trial of toripalimab in combination with chemotherapy shows significant improvement in overall survival (OS) in treatment-naïve patients with advanced non-small-cell lung cancer (NSCLC) without EGFR/ALK driver mutations.

In the phase II/III ENRICH trial, first-line (1L) ibrutinib with rituximab (IR) demonstrates superiority over rituximab plus chemotherapy (R-chemo; either R-CHOP* or bendamustine**-R) in older patients with previously untreated mantle cell lymphoma (MCL).

Women with large breasts are at greater risk of developing breast cancer, reveals a study, indicating the important role of mammographic density as first measured in determining subsequent risk.